These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31176543)

  • 1. Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
    Weeda ER; Cassarly C; Brinton DL; Shirley DW; Simpson KN
    J Diabetes Complications; 2019 Aug; 33(8):567-571. PubMed ID: 31176543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Loop Diuretic Dosing Following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure.
    Trudeau BM; Allen LA; Billups SJ; Saseen JJ; Pearson SM
    J Pharm Pract; 2023 Dec; 36(6):1330-1335. PubMed ID: 35848505
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study).
    Patil T; Halsey E; Kaur A; Minchak J; Hobson J; Eppes D
    Clin Drug Investig; 2023 Jan; 43(1):61-74. PubMed ID: 36515856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
    Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
    Shiina K; Tomiyama H; Tanaka A; Imai T; Hisauchi I; Taguchi I; Sezai A; Toyoda S; Dohi K; Kamiya H; Kida K; Anzai T; Chikamori T; Node K;
    Hypertens Res; 2023 Feb; 46(2):495-506. PubMed ID: 36380202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
    Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
    Rao VS; Ivey-Miranda JB; Cox ZL; Moreno-Villagomez J; Maulion C; Bellumkonda L; Chang J; Field MP; Wiederin DR; Butler J; Collins SP; Turner JM; Wilson FP; Inzucchi SE; Wilcox CS; Ellison DH; Testani JM
    J Am Soc Nephrol; 2024 Feb; 35(2):189-201. PubMed ID: 38073038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
    Gonzalez J; Dave CV
    BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.
    Alshnbari A; Alkharaiji M; Anyanwagu U; Idris I
    Curr Med Res Opin; 2020 Dec; 36(12):1985-1989. PubMed ID: 33085525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.